|
|
|
Anthony Amato
Vice President Business Development
Lupin Pharmaceuticals
Anthony started in the industry at Barr Laboratories after practicing law in New York for a number of years. At Barr he was responsible for M&A and licensing
involving branded and generic drugs. Mr. Amato left Barr in 2006 to join Quadrant Capital, a merchant bank focused on specialty pharmaceuticals, where he
was responsible for sourcing investment opportunities, building management teams and arranging equity and debt financing. In 2009, Anthony joined Lupin
Pharmaceuticals and he is responsible for Generic and Branded business development opportunities including M&A and licensing.
_____________________________________________________________________________________________________________________________
|
|
|
|
Kimberly Belsky, MS
Executive Director, Policy & Communication
Global Pharmaceutical Regulatory Affairs
Bausch + Lomb
Kim is the director of policy and communication, global regulatory affairs pharmaceuticals at Bausch & Lomb and has held positions of various levels at
Schering-Plough and Wyeth (now Pfizer). She has 20 years’ pharmaceutical experience, a broad understanding of the pharmaceutical industry and the
challenges it faces. Belsky began her career in research and development and technology transfer, moved into a quality control position assessing out-of-spec
results and then transitioned into drug development where she managed a GMP auditing function. For the past 11 years, she has held a regulatory role with
global responsibilities that include advertising and promotion, labeling, information management, auditing and regulatory intelligence. Belsky holds an MS in
chemistry from SUNY Stony Brook and has several scientific publications. She is also a member of RAPS and DIA.
_____________________________________________________________________________________________________________________________
|
| |
|
David Benharris
Senior Vice President
DARA Biosciences
_____________________________________________________________________________________________________________________________
|
| |
|
Steve Bloom
Senior Vice President Commercial Strategy, Business Development and Advocacy Relations
ZIOPHARM Oncology
Steven Bloom joined ZIOPHARM Oncology in March 2008 and is currently Senior Vice President of Commercial Development, Business Development and
Advocacy Relations. Steve is responsible for developing the business strategy for the oncology portfolio including commercial assessment, reimbursement
planning and competitive analysis. Prior to his role at ZIOPHARM Oncology, Steve was Vice President of Business Development at Pharmetrics, Inc (which
was acquired by IMS Health in 2005) which focused on health outcomes analysis, market analytics and economic modeling. Steve spent the first 20 years of
his career at Eli Lilly and Company in commercial and government affairs roles with increasing responsibility in marketing management, managed care, sales
management and public policy. In his career, Steve has led or participated in the evaluating, structuring and negotiating of numerous licensing transactions
including ZIOPHARM’s recent collaboration with Solasia Pharma, KK. In Japan.
Steve holds a Pharmacy degree from Northeastern University in Boston and is currently Adjunct Faculty Member at the University of Rhode Island College of
Pharmacy in Kingston, RI.
_____________________________________________________________________________________________________________________________
|
|
|
|
Linda Bowen, RAC, FRAPS
Head of US Regulatory Policy and Intelligence, Global Regulatory Policy and Intelligence, Global Regulatory Affairs
Sanofi
Linda is Head of US Regulatory Policy and Intelligence at Sanofi-Aventis and has held senior regulatory positions at Bayer Healthcare and GlaxoSmithKline.
She holds an MS in drug regulatory affairs from the Arnold & Marie Schwartz College of Pharmacy, where she was inducted into the Rho Chi Society. She is
regulatory affairs certified (RAC) for the US, Canada and Europe. She is a member of DIA, RAPS, the RAPS Board of Directors (two-term), Chair of the RAPS
NJ/NY Chapter, past chair of the RAPS Annual Conference global briefings track and the first Canadian RAPS Conference, a contributing author in RAPS,
Choosing the Right Regulatory Career, editor of the first edition of Fundamentals in Canadian Regulatory Affairs, and co-author of Regulatory Focus magazine
articles on regulatory intelligence tools. She has spoken at numerous RAPS and DIA conferences and events. She is past chair of the Regulatory Intelligence
Network Group, a working group under the DIA Regulatory Affairs SIAC and is an adjunct professor in Temple University's QA/RA program.
_____________________________________________________________________________________________________________________________
|
| |
|
Millie Cason
Director, Competitive Intelligence
Astellas Pharma
Millie Cason is the Director of Competitive Intelligence for Astellas Pharma US . Ms. Cason has over 15 years of experience in competitive
intelligence, strategy and decision support for companies including Astellas, Amgen and Abbott.
In current and previous roles, Ms. Cason has spearheaded the establishment of the competitive intelligence function. She has extensive experience and
success in developing and implementing early warning systems, business war games and global monitoring programs that support brand management,
marketing, regulatory and R&D functions.
_____________________________________________________________________________________________________________________________
|
| |
|
Linda Cherry
New Product Development- US
Ipsen Biopharmaceuticals
_____________________________________________________________________________________________________________________________
|
| |
|
Robert Constable
Director, Corporate Strategic Intelligence
Sanofi Pasteur
_____________________________________________________________________________________________________________________________
|
| |
|
Eileen Faucher, PhD
Associate Director, Business Development
Sarepta Therapeutics
_____________________________________________________________________________________________________________________________
|
| |
|
Stephanie Fitch
Executive Director, Commercial Operations
Regeneron Pharmaceuticals
_____________________________________________________________________________________________________________________________
|
| |
|
Aaron Furtado
Senior Director, Business Planning, Market Research, & Business Analytics
Ipsen Biopharmaceuticals
Aaron Furtado currently heads market research and analytics at Ipsen US at their endocrinology franchise. He came to Ipsen with significant experience in the
pharmaceutical industry in positions of increasing scope and responsibility. He has expertise in US market research (primary and secondary), forecasting,
competitive intelligence, strategic planning, communications and sales operations. He has been recognized as an effective leader and team player with an
entrepreneurial spirit and awarded for providing critical analytical solutions to support the business.
He was till recently responsible for the internal and external leadership for measurement, analytics, primary and secondary research, CI, forecasting and
Executive management reporting functions at Noven Pharmaceuticals Inc, a fully owned US subsidiary of Hisamitsu. The scope of ownership for this position
included all inline products, pipeline products, and analytics supporting business development. This role required in-depth experience with a variety of
measurement and research methods, forecasting techniques, therapeutic areas and reporting and analytic platforms. This also included managing team
members with varied industry experience. A critical component of this job was to develop comprehensive analytic and fact based communications that
influenced decision making to drive greater revenue and value.
Aaron has a Bachelors in Electronic and Telecommunications engineering and an MBA in Marketing and started his career as a sales representative.
_____________________________________________________________________________________________________________________________
|
|
|
|
Omar Gaya
Strategic Intelligence
Regeneron
_____________________________________________________________________________________________________________________________
|
| |
|
Eric Gornstein
External Insights, Innovative Medicines Strategy New Opportunities
AstraZeneca
_____________________________________________________________________________________________________________________________
|
|
|
|
Jeff Henderson
Vice President, Managed Markets
Vertex Pharmaceuticals
Jeff Henderson is the Vice President of Managed Markets at Vertex Pharmaceuticals, Inc, a position he has held since October 2010. In this position, Jeff is
responsible for the Managed Markets Organization overseeing the Account Management, Trade Relations & Distribution, Managed Markets Marketing, and
Pricing & Contract Administration functions.
Prior to joining Vertex Pharmaceuticals, Inc., Jeff spent 19 years working for Pfizer, Inc. where he held numerous leadership positions within Pfizer’s US sales
and managed markets organization. Jeff also served as an officer in the United States Army and Army Reserve for 15 years where he attained to rank of Major.
Jeff graduated with a Bachelor of Arts in History from the Virginia Military Institute.
_____________________________________________________________________________________________________________________________
|
|
|
|
Norihisa Iwakami
Manager of Scientific Intelligence, CMSO Office
Takeda Pharmaceutical Company
Norihisa Iwakami is now Manager of Scientific Intelligence, CMSO Office in Takeda Pharmaceutical Company.
Norihisa Iwakami has worked for over 18 years several organization in Takeda Company; Pharmaceutical Research Div., Strategic Product Planning Dept.
Manager of Scientific Intelligence (SI) in CMSO Office (2008-present):
Norihisa Iwakami has taken part in team’s intelligence projects as follows;
- Competitors intelligence database
- Trend analysis of pharmaceutical company/industry
- Trend analysis of emerging market dynamics
Education:
Master’s degree, “Research of the biosynthesis of polyketides in filamentous fungus”; Pharmaceutical science, Tokyo University.
_____________________________________________________________________________________________________________________________
|
|
|
|
Kirsten Kliwinski
Senior Director
DSM Pharmaceutical
Kirsten Kliwinski is Senior Director at Royal DSM, N.V. Kirsten leads an intelligence team located in the US and EU, supporting the strategic and tactical
intelligence needs of three DSM contract manufacturing business units: Biologics, APIs and Secondary Manufacturing. Prior to joining DSM, Kirsten held
positions within Pfizer Rx and OTC groups as well as Novartis Pharmaceuticals supporting a variety of therapeutic areas in R&D, Marketing, Sales,
Manufacturing and New Business Development . Kirsten holds an MBA from Rider University and a BS in Biochemistry from Albright College.
_____________________________________________________________________________________________________________________________
|
|
|
|
Dawn Kumiega
Associate Director, Head of Competitive Intelligence
Shire Pharmaceuticals, Rare Diseases Business Unit
Dawn is currently the Head of the Competitive Intelligence function for the Rare Diseases Business Unit at Shire. She leads the development of the function to
meet current and future business needs as well as all current competitive intelligence for 5 in-line products, multiple pipeline programs and research diseases
of interest. Before promotion to this role, Dawn was a member of the global analytics team performing forecasting/analytics, market research and CI for the
above mentioned products and programs and as Program Manager for Replagal, Shire’s Fabry disease product. Before joining Shire in 2006, Dawn worked at
Millennium Pharmaceuticals in a variety of roles. She holds Bachelor and Master Degrees in Music and an MBA from Simmons School of Management.
_____________________________________________________________________________________________________________________________
|
| |
|
Gerald Kunze
Associate Director, Market Research & Business Analytics
CSL Behring
Gerald Kunze is the Associate Director of Market Research & Business Analytics for CSL Behring, a $4 billion biopharmaceutical firm specializing in plasma
products and flu vaccines. His principle responsibilities include management of competitive intelligence, business analytics and market research for the
entire U.S. operation. Mr. Kunze’s group supports decision-making for the full range of businesses within CSL including immunology, bleeding disorders and
other rare diseases.
In addition to the functions he currently supports, Mr Kunze’s work experience spans a range of functional areas including marketing & sales, corporate
planning, finance, engineering and manufacturing.
Prior to his career in pharmaceuticals, he worked as a business consultant and corporate planner in the environmental and chemical industry.
Mr. Kunze formerly served as an adjunct professor of business in the Penn State system.
He earned his BSE in Chemical Engineering from Princeton University and a MBA from the University of Pittsburgh.
_____________________________________________________________________________________________________________________________
|
| |
|
Penny Levin, MS
Director Global Regulatory Intelligence & Policy
Teva Global Branded Products
Penny Levin leads the new regulatory intelligence function at Cephalon where she provides analysis of the regulatory environment; including review of and
developing Cephalon interpretation on forthcoming legislation and guidance that impact drug development and then training internal personnel to assure
understanding and compliance with the new regulations. In this role, Penny also provides strategic guidance to the product development teams by using
regulatory intelligence as a tool for better decision-making. Penny also represents Cephalon on the BIO Regulatory Affairs and PDUFA V workings groups in
efforts to assure that FDA legislation and guidances that impact drug development are developed with appropriate input from industry.
Penny has more than 20 years experience as a regulatory affairs and clinical research professional. Prior to starting up the regulatory intelligence function,
Penny was the Regulatory Director for multiple drugs in the pain franchise at Cephalon. Prior to joining Cephalon, Penny has had tenure at major
pharmaceutical companies including AstraZeneca and SmithKline, as well as spent a number of years at Hurley Consulting where she provided drug
development counsel to numerous pharmaceutical and biotech companies worldwide. While at AstraZeneca, Penny brought the Temple University Graduate
School of Pharmacy Master’s Degree program in Regulatory/QA on-site to provide employees an opportunity to obtain their graduate studies while still on
campus. This program is still ongoing today.
Penny holds a Masters of Science in biostatistics from New York Medical College and is an alumni of Harvard Business School where she completed the
General Management Program.
_____________________________________________________________________________________________________________________________
|
|
|
|
Robert B. Lieberman
Associate Director, Global Competitive Intelligence
Bayer Healthcare Pharmaceuticals Inc.
Robert Lieberman has been a CI manager/practitioner for nearly 25 years. He began his CI career as a project manager and editor at Washington Information
Group (WIG), a pioneer CI consultancy that was a founding SCIP member. Subsequently, he became research director of WIG’s CI practice before becoming
a CI practitioner in the pharmaceutical industry.
Bob started the commercial CI operation at The Upjohn Co. in 1994 and was integral in helping establish and grow the CI groups at successor companies
Pharmacia & Upjohn and Pharmacia. He later helped start and develop the CI group at a mid-tier pharmaceutical company. He currently is associate director
of global CI at Bayer Heathcare Pharmaceuticals, and based in Montville, New Jersey.
_____________________________________________________________________________________________________________________________
|
| |
|
Michele Maier
Director, Market and Competitive Insights Group
Boehringer Ingelheim Pharmaceuticals
Michele Maier-Clap is currently Director of Marketing and Competitive Insights at Boehringer Ingelheim Pharmaceuticals Inc orporated. She joined the
company in 1990 and has worked in diverse roles of increasing responsibility since that time, including earlier managerial roles in Trade Relations as well as
Professional Relations and Education. The majority, and most recent years, of her professional career have been in Brand Marketing (Cardiovascular and CNS)
and Competitive Intelligence. She has been recognized by BIPI for her performance and leadership, and recent awards include:
- Team Leader, Marketing Team of the Year (2010)
- Boehringer Ingelheim Marketing Leadership of the Year Award (2009)
- Spotlight Award for co-leadership in development of novel contracting strategy for CNS launch
- Led development of Milestones in PD, a DVD which won Aurora Best in Show/ Platinum Award based on creativity, message effectiveness and
technical excellence.
- Team Spirit Award for leadership of successful task force that informed brand strategy around competitors. (2008)
- Champion Award for leadership role in the development of a Marketing Training Module entitled “Understanding the Market to Gain Competitive
Advantage” (2008)
- Best Application of Strategic Analysis In Marketing (2007)
- CNS Leadership Award (2007)
Michele has a Bachelor of Arts in English from Western Connecticut State University and an MBA from WCSU’s Ancell School of Business.
_____________________________________________________________________________________________________________________________
|
| |
|
So Man
Information Analyst
AstraZeneca
So is an Information Analyst having worked for AstraZeneca for over 11 years. In that time, So has undertaken a number of roles in information and competitive
intelligence support to early projects and brands in Sweden and the USA. So is currently chairing a Competitive Intelligence Community of Practice within
AstraZeneca with the objective of raising the awareness of CI and improving analysis skills in-house. Prior to this, So worked in Aventis in the UK as an Scientist
and an Information Scientist and it is in the latter role that she developed a passion for CI.
_____________________________________________________________________________________________________________________________
|
| |
|
Kevin McDermott
Vice President, Managed Markets
Aptalis Pharma
Kevin has over 26 years of pharmaceutical sales and marketing experience.
His career began with Parke-Davis where he spent 15 years in various positions within Sales and Sales Leadership. In 1990 he began a concentration in
business to business (B2B) relationships (otherwise known as managed markets), highlighted by his leadership of the launch of Lipitor® . In 2000 he continued
to focus on linking B2B priorities while at Sanofi Pasteur where, among other accomplishments, he led the creation of a new service model for the company’s
adolescent and adult vaccine portfolio. In 2004 Kevin went to Daiichi Sankyo where he established a culture of managed markets leaders working with
customers to prepare their organizations to be consumer centric in their markets.
Since May 2012, Kevin has led the Aptalis Pharma, Inc. Managed Markets Team which directs the company’s interactions with health plans, PBMs, VA/DoD,
hospital systems, specialty pharmacy and multi-specialty physician groups.
_____________________________________________________________________________________________________________________________
|
| |
|
Michael Mcfadden
Vice President US Sales and Managed Markets
Avanir Pharmaceuticals
_____________________________________________________________________________________________________________________________
|
| |
|
Andrea Mulford
Head, Global Medicines Insight
Teva Branded Products
_____________________________________________________________________________________________________________________________
|
|
|
|
Marjorie Norman
Director, Worldwide Competitive Intelligence
Pfizer
Marjorie G. Norman is Director, Worldwide Competitive Intelligence for Pfizer, specializing in providing business and competitive intelligence to senior R&D
management. Prior to joining Pfizer in 2002, she was Director – Pharmaceutical Practice, at Fuld & Company, a competitive intelligence consulting firm and
a Senior Market Research Analyst at Johnson & Johnson Professional. Ms. Norman holds an MBA from the Graduate School of Management at Simmons
College and a BA in German and art history from Franklin & Marshall College. She recently returned from a six-month deployment at Population Services
International in Nairobi, Kenya, as part of the Pfizer Global Health Fellows program.
_____________________________________________________________________________________________________________________________
|
|
|
|
Daniel Pascheles, Ph.D.
Vice President, Head Global Competitive Intelligence
Merck & Co.
Dr. Daniel R. Pascheles is Head, Global Competitive Intelligence, and is based in Whitehouse Station NJ, at the Global HQ of Merck & Co., Inc.
His responsibilities include providing intelligence regarding business, research and development activities of competitors, as well as participating in, and
contribution to the strategy development process, the target identification for licensing and M&A activities.
Pascheles joined Merck & Co., Inc. early 2005 from Aventis Inc. where he was Vice President and head of Corporate Competitive Intelligence. He has worked
for Aventis and its predecessor company (Hoechst Marion Roussel, Marion Merrell Dow) for 14 years in various positions and locations.
Pascheles studied Pharmacy at the Swiss Federal Institute of Technology in Zurich, Switzerland. He received his Ph.D. in Pharmaceutical Technology from
the same university. He has done additional study at the University of Kansas in Lawrence, Kansas.
Pascheles is Past-President and current Board member of the Pharmaceutical Business Intelligence & Research Group (PBIRG). He is also member of the
Society of Competitive Intelligence Professionals (SCIP) and the Licensing Executive Society (LES).
_____________________________________________________________________________________________________________________________
|
|
|
|
Christopher Perkins
Head of Market Insights - Diabetes Care
Roche Diagnostics
Christopher Perkins currently manages the Business Intelligence function for Roche Diabetes Care. Mr. Perkins has a BA (Hamilton College) and an MA (Penn.
State) in Mathematics.
Before coming to Roche, Mr. Perkins worked as a Market Research Manager in IBM’s PC Division. Prior to his current role at Roche, Mr. Perkins was Manager of
Market Research and also held an international assignment in Switzerland as Head of Market Insight and Analysis for Roche’s Insulin Pump business.
Mr. Perkins has had the opportunity to sit on the American Marketing Association’s Advanced Research Techniques program committee and has published in
the SIAM Journal of Numerical Analysis.
_____________________________________________________________________________________________________________________________
|
| |
|
Kim Quaintance
Senior Director, Global Regulatory Policy and Intelligence Global Regulatory Affairs
Eisai, Inc.
As Senior Director, Global Regulatory Policy and Intelligence at Eisai, Inc., Ms. Quaintance is responsible for providing support to the Global Regulatory
Affairs organization in the areas of regulatory policy and intelligence. This includes efforts to influence health authority positions on initiatives and programs,
both proactively and in response to regulatory documents or policy proposals, via development of written comments and participation on internal and external
working groups and committees. She is also responsible for providing targeted regulatory information and strategic advice to staff in support of product
creation and development, providing training sessions on relevant regulatory topics, and assisting with the development of internal policies and procedures.
Ms. Quaintance joined Eisai in 2011 after 14 years at FDA’s Center for Drug Evaluation and Research, serving as the Associate Director for Regulatory Affairs in
the Office of New Drugs (OND). As part of the Senior Leadership Team in OND, she worked with the Director and Deputy Director to plan, coordinate and review
the activities of OND, including the development, documentation, and implementation of policy, procedures, and quality systems approaches related to IND
and marketing application review. Ms. Quaintance holds a Bachelor of Science in Biochemistry from the University of Illinois, Urbana-Champaign.
_____________________________________________________________________________________________________________________________
|
|
|
|
Chandra Ramanathan
Head, Early Pipeline Oncology - Global Marketing
TA Oncology, Specialty Medicine BU
Bayer HealthCare Pharmaceuticals
Dr. Chandra Ramanathan has been associated with pharmacy academia and pharmaceutical industry for more than 22 years. He has successfully applied
scientific insights to address business issues in oncology, immunology, Neuroscience and gastroenterology. He has extensive experience in Identifying new
licensing/business development opportunities and conducting scientific and commercial due diligence on both compounds and technology deals.
Dr. Ramanathan has contributed to the launch of Orencia (Biologic; Rheumatoid arthritis) and Sprycel (small molecule; Chronic Myelogenous Leukemia) by
incorporating competitive insights in marketing strategy development and execution. He has worked across the product development and commercialization
spectrum from discovery, clinical development to marketing. He has successfully worked in new product planning/product commercialization and has
contributed to the development of clinical and commercial strategy for early and late-stage compounds. He also played a key role in evaluating biosimilars
for potential opportunities and assessing risk for the commercial franchise.
_____________________________________________________________________________________________________________________________
|
|
|
|
Alfred A. Reszka, PhD
Executive Director Strategic Planning, Intelligence & Analytics
Global Competitive Intelligence
Merck
Alfred "Al" Reszka is an Executive Director Strategic Planning, Intelligence & Analytics within Corporate Business Development at Merck & Co. with
responsibility covering the Respiratory & Immunology Franchise and Merck BioVentures. His primary internal clients include respective Research and
Development teams, New Products Marketing, and all Brand Teams in the biosimilars, respiratory and immunology space. Al is responsible for understanding
the activities of all relevant pharmaceutical companies with an eye to understand their relative positioning in each of the therapeutic areas of interest. Roles
and responsibilities include strategy development, licensing and business development, and M&A.
Prior to joining the Global Competitive Intelligence group at in 2007, Dr. Reszka was Senior Research Fellow in Bone Basic Research at Merck. In this role he
led the effort in discovering the molecular and cellular mechanism of action of the osteoporosis treatment, FOSAMAX. Over the years, he expanded his
responsibilities to include leadership over osteoanabolic drug discovery at Merck. He is the author of many peer-reviewed scientific articles, book chapters, and
reviews in the osteoporosis area.
Dr. Reszka's academic credentials include a Ph.D. in Cell Biology from the University of Illinois, Champaign-Urbana (1992). His thesis research focused
integrin-based cell adhesion and its interactions with the actin cytoskeleton. He conducted postdoctoral research in biochemistry and signal transduction at
the University of Washington in collaboration with the Nobel Laureates, Edmond Fischer and Edwin Krebs. From this position he joined Merck in 1997.
_____________________________________________________________________________________________________________________________
|
|
|
|
Charlie Ritrovato
Executive Director, R&D Competitive Intelligence
Pfizer
Charlie is a 25 year veteran of the Pharma and Biotech industry and has experience across a number of functional areas including regulatory affairs, clinical
and preclinical drug development, and business development. Charlie was appointed head of R&D Competitive Intelligence at Pfizer in 2009.
Charlie holds a B.S. degree in Pharmacy from the University of Connecticut at Storrs, and a Doctor of Pharmacy degree from the University of Rhode Island in
Kingston. He also completed a postdoctoral fellowship in Industrial Clinical Pharmacy at Rutgers University College of Pharmacy in New Brunswick, New
Jersey.
_____________________________________________________________________________________________________________________________
|
| |
|
Will Roettger
Associate Director, Market Planning
Dendreon
_____________________________________________________________________________________________________________________________
|
| |
|
Mary Ann Sarao
Director, Global Regulatory Intelligence, US Policy & Regulatory Intelligence
Pfizer Inc.
_____________________________________________________________________________________________________________________________
|
| |
|
Indra Sethy-Coraci
Principal Analyst
Boehringer Ingelheim
Indra Sethy-Coraci joined Boehringer Ingelheim Pharmaceuticals in 2004 after completing her postdoctoral studies at Columbia University and is now a
Principal Analyst in the Competitive Technical Intelligence group supporting autoimmune diseases/immunology. Prior to graduate school, her other
industry experience includes approximately five years at Genentech in the departments of Manufacturing, Process Development Sciences and Cardiovascular
Research.
Dr. Sethy-Coraci received a B.S. in Chemical Engineering at the University of California, Davis, a PhD in Biochemistry at the Albert Einstein College of
Medicine and completed her postdoctoral training in the laboratory of Dr. Samuel C. Silverstein in the department of Physiology and BioPhysics at Columbia
University. Her postdoctoral research focused on understanding the role of mononuclear phagocytes in inflammation in Alzheimer’s disease and
atherosclerosis.
Dr. Sethy-Coraci is a member of the New York Academy of Sciences and the Society of Competitive Intelligence Professionals.
_____________________________________________________________________________________________________________________________
|
|
|
|
Arjan Singh
Director, Portfolio Strategy
Endo Pharmaceuticals Inc.
Lecturer, Strategy, Paul Merage School of Business, University of California, Irvine
Arjan Singh has worked in international corporate strategy and competitive intelligence for over 16 years. He has advised leading multinational companies in
healthcare, technology, energy, consumer goods and business services - he helped them take strategic action supported by actionable and evidence based
intelligence processes and deliverables.
Over the past decade, he has educated over two thousand people in the concepts of strategy and competitive intelligence at various venues including the
University of California, Academy of Competitive Intelligence (ACI), Society of Competitive Intelligence Professionals (SCIP) and in specific in-house sessions
at various companies
_____________________________________________________________________________________________________________________________
|
| |
|
Natasha Shah
Associate Director, R&D Strategic Relations
Amylin Pharmaceuticals, Inc.
_____________________________________________________________________________________________________________________________
|
|
|
|
Eric R Sjogren, MS, MBA, RPh
Director, Strategic Business Intelligence
Merck & Co., Inc.
Eric Sjogren is Director, Strategic Business Intelligence, within Merck’s Global Competitive Intelligence group, responsible for proving global competitive
analysis, strategic insights, implications and recommendations to Merck executives and global marketing teams. His primary area of responsibility is the
Immunology Franchise, with particular focus on the evolving biosimilar landscape and the new novel orals, as well as the regulatory environment. He also
provides strategic support to the Diversified Brands team. During his career at Merck, Eric has also held positions in Global Marketing Communications working
with marketing on a broad range of brands, and was department head of Merck Creative Services. Prior to joining Merck in 2001, Eric was with Knoll
Pharmaceuticals, has worked in pharmaceutical advertising, hospital and managed care consulting, as well has extensive clinical experience in the hospital
and community pharmacy settings.
Eric is a registered pharmacist in New Jersey, whose academic credentials include a BS in Pharmacy from Rutgers University, an MS in Hospital Pharmacy
Administration from Long Island University and an MBA in Marketing from Fairleigh Dickinson University.
_____________________________________________________________________________________________________________________________
|
| |
|
Marcio Souza
Executive Director, Marketing
NPS Pharmaceuticals
_____________________________________________________________________________________________________________________________
|
| |
|
David Stefanoni
Head, Early Stage Commercialization
Upsher-Smith Laboratories
_____________________________________________________________________________________________________________________________
|
|
|
|
Bryan Takasaki, Ph.D.
Director, External Insights
AstraZeneca
Bryan joined Astra in 1996 after completing a Chemistry post-doc at Caltech. After helping establish the combinatorial and parallel synthesis group in
Montreal, he transitioned to informatics and set up the rapid application development group. In 2000, he moved to Boston and led the chemoinformatics and
later the bioinformatics groups there. In 2005 he joined the translational science group as a project/programme manager where he worked closely with teams
developing the biomarker and personalized healthcare strategy for the Oncology portfolio. He returned to the Informatics group in 2009 to lead the
Competitive Intelligence domain within the AZ Knowledge Engineering (KE) initiative. Bryan rejoined the Oncology research group as the External Insights
director in January 2012 where he drives the competitive intelligence strategy for the Oncology Innovative Medicines group.
_____________________________________________________________________________________________________________________________
|
|
|
|
Sue Ward
Senior Director, Worldwide Competitive Intelligence
Pfizer
Sue Ward is currently Senior Director of Worldwide Competitive Intelligence within Pfizer’s Strategy and Portfolio Management group. Previously within Pfizer,
Sue led the competitive intelligence team within Information & Knowledge Management. Prior to joining Pfizer, Sue worked in the UK as Associate Director
of Competitive Analysis for SmithKline Beecham (SB) (now GSK). Other positions held by Sue within SB included managing a Clinical Information group and
the Product Literature Information Service. Sue holds a BSc (Hons) in Biology from University College London and an MSc in Information Science from The
City University, London.
_____________________________________________________________________________________________________________________________
|
|
|
|
Friederike Wirtz-Brugger, Ph.D
Director, CI Pharma Products
Sanofi-Aventis
Twenty eight years experience in Pharmaceutical research both as a Research Scientist and Senior Manager of Scientific Competitive intelligence
Senior Manager, Scientific Competitive Intelligence (SCI) , Sanofi-Aventis, US and France (2003 - present)
- Providing and managing intelligence analyses of the competitive landscape for cardiovascular and
thrombosis indications as part of a global SCI group.
- Evaluation of competitor strategies, identification of trends and product licensing opportunities for
French managed company.
- Effective global communication of interpretation and recommendations based on competitive
analysis to the research community in US , France and Germany and global marketing and
development project teams.
Senior Research Scientist, Aventis Pharma, US and Germany (until 2003)
- Managing and leading several early drug discovery and research project teams in the area of multiples sclerosis and inflammatory neurological
disease processes.
- Extensive knowledge in disease areasof CV, Thrombosis and CNS.
- Played a leadership role in Aventis / Millennium Collaboration as a representative on both target
identification and validation teams.
Education:
Ph.D., Physiology and Neurobiology, UMDNJ (The University of Medicine and Dentistry of New Jersey) and Rutgers University, Graduate School, NJ, USA.
Diplom-Ingenieur, M.S. degree / Chemical and Biomedical Engineering, University Giessen, Germany.
____________________________________________________________________________________________________________________________
|
|
